GLP-1s improved outcomes in patients with heart failure with preserved ejection fraction, with or without obesity, but those ...
A recent study found that Glucagon-like peptide-1 (GLP-1) receptor agonist use in hypertrophic cardiomyopathy (HCM) patients ...
A new device called Barostim is helping heart failure patients at Christ Hospital in Cincinnati live more normal lives ...
Beta3-adrenergic receptors (β3-AR) have emerged as pivotal modulators of cardiac performance, particularly in the context of heart failure. Distinct from the classical β1/β2-adrenergic signalling ...
Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...
Role of the RAAS in the Pathophysiology of Heart Failure ACE inhibitors have no effect on angiotensin II formed by alternate pathways. In contrast, ARBs would be expected to inhibit the biologic ...
Some studies point to melatonin use as beneficial to heart health, while others say the opposite. Here’s how to make sense of ...
A research team in Sweden has developed a new class of oral medicines aimed at type 2 diabetes and obesity, built around a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results